Breast CancerMammobileNCT05164874
A Randomized Cluster Trial to Evaluate a Mobile Mammography Unit in Breast Cancer Screening in France (Mammobile)
A study testing Mobile Mammography Unit in people with Breast Cancer, run by Université de Caen Normandie at 1 site in France.
Trial summary
Organized breast cancer screening (OBCS) has been implemented nationwide since 2004 inFrance, but the participation rate remains low (51%) and inequities in participation were reported. Read more about this study
- Who is it for?
- Ages 50 to 74 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Mobile Mammography Unit
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 91,982 participants
- Where
- 1 siteFrance
- Study dates
- 14 Feb 2022to Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 74 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- women eligible to breast cancer screening campaign : aged 50 to 74 years, and with the only risk of breast cancer being age. The previous screening mammography dating from 22 months
Who cannot join
- outside the ages
- with specific risk of breast cancer
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of a Mobile Mammography Unit. A Randomized Cluster Trial Protocol of a Population Health Intervention Research to Reduce Breast Cancer Screening Disparities in Normandy, France (Mammobile)
Organized breast cancer screening (OBCS) has been implemented nationwide since 2004 inFrance, but the participation rate remains low (51%) and inequities in participation were reported. Strategies as mobile mammography units could be effective to increase participation in OBCS and reduce inequities, especially in underserved areas in regard to this screening. Our main objective is to evaluate this device and to identify how to incorporate a mobile unit in the OBCS with a view to tackle territorial inequities in OBCS participation. The project will be conducted as a randomized controlled cluster trial in 2022-2024, in remote areas of 4 French departments. The main intervention is to propose an appointment at the mobile unit in complement to the current OBCS in these remote areas. In addition, few weeks before this intervention, local actors will carry out actions to promote OBCS with mobile unit specific information tools. This randomized controlled trial will provide a high level of evidence in assessing the mobile unit effects on participation and inequities.
Read the detailed description
Context In most EU member states, breast cancer screening is organised with a mammography screening. However, there are still differences in the way screening programmes are implemented. In France, the organized breast cancer screening (OBCS) has been conducted, nationwide since 2004. A screening mammography is offered every two years to women aged 50 to 74 at average risk for this cancer. They receive from management structures in charge of this screening (SMS), an invitation to visit an accredited radiologist's office. A radiological imaging of the breast with two views plus a clinical breast examination is realized. Two different radiologists assure readings. In the last three year, the national participation rate remains stable around 51%. In addition, studies, using ecological indices of deprivation, highlight social and territorial inequalities: women living in disadvantaged area or far from a radiologist's office less participate. Different strategies can be implemented to increase participation to breast cancer screening, especially in populations with low-income or in rural areas, who have less access to screening. Among these strategies, mobile mammography units (MMU) seem effective. Therefore, in the French context, there is very little evidence on how to intervene to reduce health socio-territorial inequalities in screening, so public health decision-makers are unable to base proposals on evidence.
Intervention The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS. This complementary mode of screening offers the possibility for women furthest away from the radiologist's office to undergo screening in the MMU. All women eligible for OBCS and living in the zone selected for the intervention will be invited to participate either in a radiologist's office or in the MMU, keeping the choice of their place of screening. The breast screening in the MMU will follow the same protocol as screening at the radiologist's office according to national recommendations, so that the quality level of screening proposed in the MMU will the same as in any radiologist office. The MMU will be equipped with a latest-generation digital scenographer as well as an ultrasound system according to the compliance rules of the specifications published by the National Institute of Cancer. The quality of the mammographic radiographic equipment will also be certified by the Nuclear Safety Agency.
About two weeks before the MMU is parked, local actors, will carry out actions to inform women on the organized breast cancer screening and on the MMU. Women will receive the timetable of these actions with the invitation to participate in screening.
Design This intervention will be conducted during two years in 2022-2024, as a prospective randomized controlled cluster trial in the general population in the departments of Calvados, Manche, Eure and Seine-Maritime (Normandy Region in the north west of France). The cluster of the study is a group of IRIS (Ilots Regroupés pour l'Information Statistique). This geographical unit is the smallest scale for which census data are available and represents an average of 2000 inhabitants.
An algorithm was developed to constitute clusters integrating some constraints in a regional scenario.
Aggregation of IRIS was done according to the travel time to the radiology centres, the most distant IRIS has been selected and then merged with neighbouring IRIS, still by distance run, until reaching areas of the expected population size. This except size is around 100 women. Expecting a 40% participation to the MMU, 32 to 48 mammograms daily should be performed.
This algorithm was applied to all IRIS according to distance rank, until no more aggregation was possible. 91,982 women (95.6%) and 1,067 IRIS (94.3%) were selected in the final population in 356 clusters (with 258 created by the algorithm).
All the women constituting the target population is geolocated and geocoded. Thus, for each woman, history of screening, the current date of screening invitation, IRIS of residence, level of social deprivation according to an ecological deprivation index (the European Deprivation Index) and the distance between the woman's house and the nearest approved radiologist's office are known.
A randomization in parallel group have been perform to constitute the intervention arm (n=178 clusters) and the control arm (n=178 clusters), corresponding to 45275 in intervention arm vs 46707 in control arm.
Evaluations The overall objectives of the study are to evaluate the intervention's ability a) to reduce the socio-territorial inequalities of participation in breast cancer screening in a regional area (Normandy) in setting remote from radiologist's office b) to increase participation rate and c) understand how intervention interact with contextual factors and which causal mechanisms leading to these results in order to identify the optimal modalities for extending the MMU at the national level.
Concerning the first two objectives, the main evaluation criterion will be participation in screening, measured and compared between the "intervention" and "control" arm, at the aggregate level (cluster) and individual level in intent to treat. At the aggregate level, the comparison of screening participation will allow us to measure the raw and age-standardized increase in participation due to the intervention. At the individual level, multilevel logistic regressions, taking into account cluster data, allow to assess the increase in the probability of participating in screening after adjustment of the social deprivation, age and other available individual characteristics.
Although the calculation of the number of subjects in the study came from a pragmatic approach, the intraclass correlation factor was estimated at 0.0083, which with an average area size of 318.6 women gives a design effect equal to 3.63. Thus, the minimum significant difference in participation that can be proven will be 1.5%.
Actors information action, will be prospectively registered in a dedicated database and will be include in the global model analysis.
To furthermore explore contextual effect and to provide elements of knowledge on the causal mechanisms contributing to the effectiveness of the intervention the quantitative analyses will be completed by a qualitative approach inspired by the combined approaches that have emerged in realistic randomised controlled trials, using a theory that goes beyond logic models to describe contextual mechanisms and contingencies. An intervention theory was developed and three auto questionnaires will respectively explore, the informed choice, satisfaction to realized the mammography in the mammobile and the ComB Model construct implied in the screening behaviour.
- Conditions
- Breast Cancer
- Being tested
- Mobile Mammography Unit
- Keywords
- breast cancer screening, mobile mammography unit, social and territorial inequalities, randomized cluster trial
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mobile Mammography UnitDevice
The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Women will receive a proposition for an appointment at the MMU in complement to the current screening invitation, keeping the choice of their place of screening.
Women will also receive the timetable of prevention actions with the invitation to participate in screening. Receives: Device: Mobile Mammography Unit |
| Control | No intervention | No change from the usual breast cancer screening organization |
What is being measured
The primary outcome is the main question the study is designed to answer.
Aggregated breast cancer screening participation rate 3 months after the last invitation
Participation rate will be measure at area level and compare between intervention and control arm.
Measured: 3 months after the last invitation at the end of the two years of the intervention
Individual breast cancer screening participation rate 3 months after the last invitation
It will also be assessed at indivdual level with multilevel logistic regression
Measured: 3 months after the last invitation at the end of the two years of the intervention
Impact of the mobile unit on social inequalities in screening participation
Impact of the mobile mammography unit on social inequalities will be assessed by comparing intervention and control arm. Social statut is measure with an ecological deprivation index
Measured: 3 months after the last invitation at the end of the two years of the intervention
Impact of the mobile unit on territorial inequalities in screening participation
impact of the mobile mammography unit territorial inequalities will be assessed by comparing intervention and control arm. The distance to the radiologiste center will be used as territorial mesure
Measured: 3 months after the last invitation at the end of the two years of the intervention
Secondary outcomes (5)
Informed choice to breast cancer screening for participating women
An autoquestionnaire adressed to control and intervention arm will compare the informed choice
Measured: through study completion, an average of 3 month
Informed choice to breast cancer screening for non-participating women
An autoquestionnaire adressed to control and intervention arm will compare the informed choice
Measured: Women will be considered as "non participating" 18 month after the invitation
Satisfaction to mammography
An autoquestionnaire adressed to control and intervention arm will adressed the satisfaction to the mammography screening
Measured: through study completion, an average of 3 month
Com-B Model Evaluation for participating women
An autoquestionnaire adressed to control and intervention arm will assessed if the mobile mammography unit and the prevention action have been facilitators to opportunity, motivation or capacity, to participate to breast cancer screening
Measured: through study completion, an average of 3 month
Com-B Model Evaluation for non-participating women
An autoquestionnaire adressed to control and intervention arm will assessed if the mobile mammography unit and the prevention action have been facilitators to opportunity, motivation or capacity, to participate to breast cancer screening
Measured: Women will be considered as "non participating" 18 month after the invitation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Dec 2021
- Study start14 Feb 2022 (estimated)
- Primary completionFeb 2024 (estimated)
- Study completionSep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This intervention will be conducted as a prospective randomized controlled cluster trial.The cluster of the study is an aggregation of géographical areas. It was done according to the travel time to the radiology centres, the most distant areas has been selected and then merged with neighbouring areas, still by distance run, until reaching areas of the expected population size. This except size is around 100 women. Expecting a 40% participation to the mobile unit, we will achieve 32 to 48 mammograms daily. A randomization in parallel group have been perform to constitute the intervention arm and the control arm.
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 91,982 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université de Caen Normandie
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute, France, Regional health agency, Normandy France, Pink ribbon (Ruban Rose, France), Normandy regional cancer screening coordination center, Departmental councils
- Responsible party
- Principal investigator, Élodie Guillaume, Université de Caen Normandie
- Investigators
- Elodie Guillaume, PhD, Principal investigator, Université de Caen Normandie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05164874
- Sponsor's protocol ID
- UCaenNormandie
- Acronym
- Mammobile
- Status last verified
- Nov 2021
- First submitted
- 3 Dec 2021
- Last updated
- 21 Dec 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual data is collected as part of the usual organization of organized breast cancer screening. It is the authorized structure that manages these data.
Publications
Beuriot S, Delescluse T, Delpierre C, Launoy G, Guillaume E. Development of an intervention theory for a mobile mammography unit research project for breast cancer screening. Can J Public Health. 2026 Mar;117(Suppl 1):125-135. doi: 10.17269/s41997-025-01118-1. Epub 2026 Apr 29.
PubMed 42053923Guillaume E, Rollet Q, Launay L, Beuriot S, Dejardin O, Notari A, Crevel E, Benhammouda A, Verzaux L, Quertier MC, Launoy G. Evaluation of a mobile mammography unit: concepts and randomized cluster trial protocol of a population health intervention research to reduce breast cancer screening inequalities. Trials. 2022 Jul 8;23(1):562. doi: 10.1186/s13063-022-06480-w.
PubMed 35804417
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Mobile Mammography Unit. A Randomized Cluster Trial Protocol of a Population Health Intervention Research to Reduce Breast Cancer Screening Disparities in Normandy, France (Mammobile)
- ClinicalTrials.gov ID
- NCT05164874
- Acronym / sponsor ID
- Mammobile / UCaenNormandie
- Conditions
- Breast Cancer
- Keywords
- breast cancer screening, mobile mammography unit, social and territorial inequalities, randomized cluster trial
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 91,982 participants (estimated)
- Lead sponsor
- Université de Caen NormandieUniversity, hospital or other
- Collaborators
- National Cancer Institute, France, Regional health agency, Normandy France, Pink ribbon (Ruban Rose, France), Normandy regional cancer screening coordination center, Departmental councils
- Study start
- 14 Feb 2022 (estimated)
- Primary completion
- Feb 2024 (estimated)
- Study completion
- Sep 2024 (estimated)
- First posted
- 21 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Organized breast cancer screening (OBCS) has been implemented nationwide since 2004 inFrance, but the participation rate remains low (51%) and inequities in participation were reported. Strategies as mobile mammography units could be effective to increase participation in OBCS and reduce inequities, especially in underserved areas in regard to this screening. Our main objective is to evaluate this device and to identify how to incorporate a mobile unit in the OBCS with a view to tackle territorial inequities in OBCS participation. The project will be conducted as a randomized controlled cluster trial in 2022-2024, in remote areas of 4 French departments. The main intervention is to propose an appointment at the mobile unit in complement to the current OBCS in these remote areas. In addition, few weeks before this intervention, local actors will carry out actions to promote OBCS with mobile unit specific information tools. This randomized controlled trial will provide a high level of evidence in assessing the mobile unit effects on participation and inequities.
Detailed description
Context In most EU member states, breast cancer screening is organised with a mammography screening. However, there are still differences in the way screening programmes are implemented. In France, the organized breast cancer screening (OBCS) has been conducted, nationwide since 2004. A screening mammography is offered every two years to women aged 50 to 74 at average risk for this cancer. They receive from management structures in charge of this screening (SMS), an invitation to visit an accredited radiologist's office. A radiological imaging of the breast with two views plus a clinical breast examination is realized. Two different radiologists assure readings. In the last three year, the national participation rate remains stable around 51%. In addition, studies, using ecological indices of deprivation, highlight social and territorial inequalities: women living in disadvantaged area or far from a radiologist's office less participate. Different strategies can be implemented to increase participation to breast cancer screening, especially in populations with low-income or in rural areas, who have less access to screening. Among these strategies, mobile mammography units (MMU) seem effective. Therefore, in the French context, there is very little evidence on how to intervene to reduce health socio-territorial inequalities in screening, so public health decision-makers are unable to base proposals on evidence.
Intervention The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS. This complementary mode of screening offers the possibility for women furthest away from the radiologist's office to undergo screening in the MMU. All women eligible for OBCS and living in the zone selected for the intervention will be invited to participate either in a radiologist's office or in the MMU, keeping the choice of their place of screening. The breast screening in the MMU will follow the same protocol as screening at the radiologist's office according to national recommendations, so that the quality level of screening proposed in the MMU will the same as in any radiologist office. The MMU will be equipped with a latest-generation digital scenographer as well as an ultrasound system according to the compliance rules of the specifications published by the National Institute of Cancer. The quality of the mammographic radiographic equipment will also be certified by the Nuclear Safety Agency.
About two weeks before the MMU is parked, local actors, will carry out actions to inform women on the organized breast cancer screening and on the MMU. Women will receive the timetable of these actions with the invitation to participate in screening.
Design This intervention will be conducted during two years in 2022-2024, as a prospective randomized controlled cluster trial in the general population in the departments of Calvados, Manche, Eure and Seine-Maritime (Normandy Region in the north west of France). The cluster of the study is a group of IRIS (Ilots Regroupés pour l'Information Statistique). This geographical unit is the smallest scale for which census data are available and represents an average of 2000 inhabitants.
An algorithm was developed to constitute clusters integrating some constraints in a regional scenario.
Aggregation of IRIS was done according to the travel time to the radiology centres, the most distant IRIS has been selected and then merged with neighbouring IRIS, still by distance run, until reaching areas of the expected population size. This except size is around 100 women. Expecting a 40% participation to the MMU, 32 to 48 mammograms daily should be performed.
This algorithm was applied to all IRIS according to distance rank, until no more aggregation was possible. 91,982 women (95.6%) and 1,067 IRIS (94.3%) were selected in the final population in 356 clusters (with 258 created by the algorithm).
All the women constituting the target population is geolocated and geocoded. Thus, for each woman, history of screening, the current date of screening invitation, IRIS of residence, level of social deprivation according to an ecological deprivation index (the European Deprivation Index) and the distance between the woman's house and the nearest approved radiologist's office are known.
A randomization in parallel group have been perform to constitute the intervention arm (n=178 clusters) and the control arm (n=178 clusters), corresponding to 45275 in intervention arm vs 46707 in control arm.
Evaluations The overall objectives of the study are to evaluate the intervention's ability a) to reduce the socio-territorial inequalities of participation in breast cancer screening in a regional area (Normandy) in setting remote from radiologist's office b) to increase participation rate and c) understand how intervention interact with contextual factors and which causal mechanisms leading to these results in order to identify the optimal modalities for extending the MMU at the national level.
Concerning the first two objectives, the main evaluation criterion will be participation in screening, measured and compared between the "intervention" and "control" arm, at the aggregate level (cluster) and individual level in intent to treat. At the aggregate level, the comparison of screening participation will allow us to measure the raw and age-standardized increase in participation due to the intervention. At the individual level, multilevel logistic regressions, taking into account cluster data, allow to assess the increase in the probability of participating in screening after adjustment of the social deprivation, age and other available individual characteristics.
Although the calculation of the number of subjects in the study came from a pragmatic approach, the intraclass correlation factor was estimated at 0.0083, which with an average area size of 318.6 women gives a design effect equal to 3.63. Thus, the minimum significant difference in participation that can be proven will be 1.5%.
Actors information action, will be prospectively registered in a dedicated database and will be include in the global model analysis.
To furthermore explore contextual effect and to provide elements of knowledge on the causal mechanisms contributing to the effectiveness of the intervention the quantitative analyses will be completed by a qualitative approach inspired by the combined approaches that have emerged in realistic randomised controlled trials, using a theory that goes beyond logic models to describe contextual mechanisms and contingencies. An intervention theory was developed and three auto questionnaires will respectively explore, the informed choice, satisfaction to realized the mammography in the mammobile and the ComB Model construct implied in the screening behaviour.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- This intervention will be conducted as a prospective randomized controlled cluster trial.The cluster of the study is an aggregation of géographical areas. It was done according to the travel time to the radiology centres, the most distant areas has been selected and then merged with neighbouring areas, still by distance run, until reaching areas of the expected population size. This except size is around 100 women. Expecting a 40% participation to the mobile unit, we will achieve 32 to 48 mammograms daily. A randomization in parallel group have been perform to constitute the intervention arm and the control arm.
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Device: Mobile Mammography UnitWomen will receive a proposition for an appointment at the MMU in complement to the current screening invitation, keeping the choice of their place of screening. Women will also receive the timetable of prevention actions with the invitation to participate in screening. |
| Control | No intervention | –No change from the usual breast cancer screening organization |
Who may qualify
- Ages
- 50 to 74 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- women eligible to breast cancer screening campaign : aged 50 to 74 years, and with the only risk of breast cancer being age. The previous screening mammography dating from 22 months
Key exclusion criteria (2 listed)
- outside the ages
- with specific risk of breast cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mobile Mammography UnitThe main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS | Device | Intervention |
Primary outcome
Aggregated breast cancer screening participation rate 3 months after the last invitation
Time frame: 3 months after the last invitation at the end of the two years of the intervention
Participation rate will be measure at area level and compare between intervention and control arm.
Individual breast cancer screening participation rate 3 months after the last invitation
Time frame: 3 months after the last invitation at the end of the two years of the intervention
It will also be assessed at indivdual level with multilevel logistic regression
Impact of the mobile unit on social inequalities in screening participation
Time frame: 3 months after the last invitation at the end of the two years of the intervention
Impact of the mobile mammography unit on social inequalities will be assessed by comparing intervention and control arm. Social statut is measure with an ecological deprivation index
Impact of the mobile unit on territorial inequalities in screening participation
Time frame: 3 months after the last invitation at the end of the two years of the intervention
impact of the mobile mammography unit territorial inequalities will be assessed by comparing intervention and control arm. The distance to the radiologiste center will be used as territorial mesure
5 secondary outcomes
Informed choice to breast cancer screening for participating women
Time frame: through study completion, an average of 3 month
Informed choice to breast cancer screening for non-participating women
Time frame: Women will be considered as "non participating" 18 month after the invitation
Satisfaction to mammography
Time frame: through study completion, an average of 3 month
Com-B Model Evaluation for participating women
Time frame: through study completion, an average of 3 month
Com-B Model Evaluation for non-participating women
Time frame: Women will be considered as "non participating" 18 month after the invitation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2021.
- Derived from this study: PubMed 42053923Beuriot S, Delescluse T, Delpierre C, Launoy G, Guillaume E. Development of an intervention theory for a mobile mammography unit research project for breast cancer screening. Can J Public Health. 2026 Mar;117(Suppl 1):125-135. doi: 10.17269/s41997-025-01118-1. Epub 2026 Apr 29.
- Derived from this study: PubMed 35804417Guillaume E, Rollet Q, Launay L, Beuriot S, Dejardin O, Notari A, Crevel E, Benhammouda A, Verzaux L, Quertier MC, Launoy G. Evaluation of a mobile mammography unit: concepts and randomized cluster trial protocol of a population health intervention research to reduce breast cancer screening inequalities. Trials. 2022 Jul 8;23(1):562. doi: 10.1186/s13063-022-06480-w.
- Individual participant dataSharing planned: Yes. Individual data is collected as part of the usual organization of organized breast cancer screening. It is the authorized structure that manages these data.
Related trials for Breast Cancer
RecruitingObservational study
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
Breast Cancer, Breast Carcinoma
RecruitingObservational study
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Cancer, Cancer Diagnosis
RecruitingPhase 3
Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy
Breast Cancer
RecruitingPhase 1/2
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Liposarcoma, Prostate Cancer
RecruitingObservational study
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elodie Guillaume, PhD principal investigator
Université de Caen Normandie
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mobile Mammography Unit in people with Breast Cancer, run by Université de Caen Normandie at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Aggregated breast cancer screening participation rate 3 months after the last invitation (time frame: 3 months after the last invitation at the end of the two years of the intervention). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05164874, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2021.